Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.

The biotech company already has a candidate with a tough target in the clinic for COVID-19 and plans to have four to six candidates in the clinic over the next two years following a $273m series C round.

Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.